M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 28.41 CNY 0.07% Market Closed
Market Cap: 12.2B CNY

Gross Margin
Mayinglong Pharmaceutical Group Co Ltd

46.8%
Current
44%
Average
48.7%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.8%
=
Gross Profit
1.8B
/
Revenue
3.8B

Gross Margin Across Competitors

No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
12.2B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Intrinsic Value
33.8 CNY
Undervaluation 16%
Intrinsic Value
Price
M
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
46.8%
=
Gross Profit
1.8B
/
Revenue
3.8B
What is the Gross Margin of Mayinglong Pharmaceutical Group Co Ltd?

Based on Mayinglong Pharmaceutical Group Co Ltd's most recent financial statements, the company has Gross Margin of 46.8%.

Back to Top